Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)

Inclusion Criteria: * COVID-19 PCR positive, * Hospitalized patients with illness of any duration, and/or SpO2 ≤ 92% on room air. * Cohorte C : patients with cancer (hematological malignancies and solid tumors). Exclusion Criteria: * Refusal to participate, * Any immunosuppressive therapy (i.e. corticosteroids \>10mg of hydrocortisone or equivalent dose) within 14 days before the planned start of study, * Active or chronic hepatitis B or C and/or HIV positive (HIV 1/2 antibodies patients), or a known history of active Tuberculosis bacillus, * Active autoimmune disease that required a systemic treatment, with the following exceptions: * Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study, * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study, * Prior allogeneic bone marrow transplantation or prior solid organ transplantation, * Patients currently exposed to chemotherapy, anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy or biotherapy (except for patients in cohort C), * Previous prescribing of biotherapy or treatment for the management of COVID-19 is not an exclusion criterion, * Patient under guardianship, curatorship or under the protection of justice.